Oncolytics Other Operating Expenses vs Research Development Analysis

ONCY Stock  USD 0.93  0.02  2.11%   
Oncolytics Biotech financial indicator trend analysis is much more than just breaking down Oncolytics Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oncolytics Biotech is a good investment. Please check the relationship between Oncolytics Biotech Other Operating Expenses and its Research Development accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

Other Operating Expenses vs Research Development

Other Operating Expenses vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oncolytics Biotech Other Operating Expenses account and Research Development. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Oncolytics Biotech's Other Operating Expenses and Research Development is 0.89. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Research Development in the same time period over historical financial statements of Oncolytics Biotech, assuming nothing else is changed. The correlation between historical values of Oncolytics Biotech's Other Operating Expenses and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of Oncolytics Biotech are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Other Operating Expenses i.e., Oncolytics Biotech's Other Operating Expenses and Research Development go up and down completely randomly.

Correlation Coefficient

0.89
Relationship DirectionPositive 
Relationship StrengthStrong

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Oncolytics Biotech. It is also known as Oncolytics Biotech overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Research Development

Most indicators from Oncolytics Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oncolytics Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.At this time, Oncolytics Biotech's Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to rise to about 118 M in 2024, whereas Tax Provision is likely to drop slightly above 84.1 K in 2024.
 2021 2022 2023 2024 (projected)
Interest Income98.6K528K1.2M1.2M
Net Interest Income98.6K528K1.2M1.2M

Oncolytics Biotech fundamental ratios Correlations

0.140.010.90.74-0.84-0.62-0.070.84-0.130.98-0.150.70.460.620.660.320.451.00.170.680.440.330.660.70.6
0.140.02-0.10.41-0.04-0.58-0.590.050.010.030.40.480.750.560.540.580.490.140.240.490.560.220.540.530.19
0.010.02-0.30.290.02-0.150.260.0-0.39-0.030.34-0.110.090.190.220.710.370.030.77-0.380.050.110.10.32-0.04
0.9-0.1-0.30.51-0.78-0.330.090.82-0.040.94-0.330.480.120.290.37-0.10.10.9-0.160.580.180.170.390.440.58
0.740.410.290.51-0.58-0.75-0.260.63-0.230.70.040.590.590.650.760.640.610.760.360.580.650.370.730.940.51
-0.84-0.040.02-0.78-0.580.460.03-0.950.35-0.860.26-0.54-0.31-0.58-0.48-0.13-0.4-0.84-0.13-0.56-0.34-0.06-0.53-0.52-0.23
-0.62-0.58-0.15-0.33-0.750.460.36-0.390.35-0.55-0.11-0.84-0.81-0.8-0.98-0.6-0.69-0.62-0.2-0.78-0.94-0.41-0.99-0.72-0.24
-0.07-0.590.260.09-0.260.030.360.02-0.450.03-0.05-0.51-0.68-0.61-0.24-0.29-0.62-0.03-0.24-0.52-0.44-0.38-0.37-0.270.07
0.840.050.00.820.63-0.95-0.390.02-0.340.87-0.220.410.230.470.420.180.290.860.150.460.240.10.420.590.3
-0.130.01-0.39-0.04-0.230.350.35-0.45-0.34-0.18-0.140.070.05-0.04-0.39-0.190.08-0.18-0.080.06-0.290.13-0.31-0.140.28
0.980.03-0.030.940.7-0.86-0.550.030.87-0.18-0.290.620.340.520.590.210.350.990.090.620.370.280.590.640.57
-0.150.40.34-0.330.040.26-0.11-0.05-0.22-0.14-0.29-0.10.240.120.140.430.06-0.140.28-0.110.11-0.050.050.06-0.05
0.70.48-0.110.480.59-0.54-0.84-0.510.410.070.62-0.10.810.880.810.390.770.670.110.920.790.370.890.620.35
0.460.750.090.120.59-0.31-0.81-0.680.230.050.340.240.810.880.770.710.780.440.360.690.760.470.80.660.24
0.620.560.190.290.65-0.58-0.8-0.610.47-0.040.520.120.880.880.760.640.930.60.470.750.740.390.830.690.17
0.660.540.220.370.76-0.48-0.98-0.240.42-0.390.590.140.810.770.760.630.640.660.230.720.870.310.970.740.32
0.320.580.71-0.10.64-0.13-0.6-0.290.18-0.190.210.430.390.710.640.630.690.330.760.160.490.440.540.720.19
0.450.490.370.10.61-0.4-0.69-0.620.290.080.350.060.770.780.930.640.690.430.620.570.650.350.70.650.12
1.00.140.030.90.76-0.84-0.62-0.030.86-0.180.99-0.140.670.440.60.660.330.430.170.660.430.330.660.710.59
0.170.240.77-0.160.36-0.13-0.2-0.240.15-0.080.090.280.110.360.470.230.760.620.17-0.130.030.30.170.40.0
0.680.49-0.380.580.58-0.56-0.78-0.520.460.060.62-0.110.920.690.750.720.160.570.66-0.130.750.320.820.570.39
0.440.560.050.180.65-0.34-0.94-0.440.24-0.290.370.110.790.760.740.870.490.650.430.030.750.360.930.60.08
0.330.220.110.170.37-0.06-0.41-0.380.10.130.28-0.050.370.470.390.310.440.350.330.30.320.360.390.380.17
0.660.540.10.390.73-0.53-0.99-0.370.42-0.310.590.050.890.80.830.970.540.70.660.170.820.930.390.690.26
0.70.530.320.440.94-0.52-0.72-0.270.59-0.140.640.060.620.660.690.740.720.650.710.40.570.60.380.690.52
0.60.19-0.040.580.51-0.23-0.240.070.30.280.57-0.050.350.240.170.320.190.120.590.00.390.080.170.260.52
Click cells to compare fundamentals

Oncolytics Biotech Account Relationship Matchups

Oncolytics Biotech fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets19.7M34.3M45.9M37.3M38.8M30.5M
Total Current Liabilities12.9M2.7M2.7M3.9M4.2M3.9M
Total Stockholder Equity(107.9K)24.8M36.1M26.5M27.6M17.8M
Property Plant And Equipment Net727.5K609.1K976.3K652K647K460.6K
Net Debt(13.6M)(30.8M)(40.6M)(11.3M)(34.5M)(32.8M)
Retained Earnings(344.6M)(367.1M)(393.4M)(418.3M)(446.0M)(423.7M)
Accounts Payable3.2K1.8K594K2.3M1.1M1.0M
Cash14.1M31.2M41.3M11.7M34.9M19.4M
Non Current Assets Total727.5K609.1K976.3K1.7M647K614.7K
Cash And Short Term Investments14.1M31.2M41.3M32.1M34.9M26.6M
Net Receivables2.1M89.7K866.1K521K15K14.3K
Common Stock Shares Outstanding22.1M40.3M53.5M58.0M67.6M71.0M
Liabilities And Stockholders Equity19.7M34.3M45.9M37.3M38.8M30.5M
Non Current Liabilities Total6.9M6.9M7.1M6.9M7.0M7.4M
Other Current Assets2.7M2.4M2.8M1.7M3.2M3.4M
Other Stockholder Equity33.0M31.0M37.8M40.1M42.1M38.1M
Total Liab19.8M9.6M9.8M10.8M11.3M6.0M
Property Plant And Equipment Gross1.7M609.1K976.3K652K1.3M1.4M
Total Current Assets18.9M33.7M44.9M35.7M38.2M28.0M
Accumulated Other Comprehensive Income464.1K400.2K387.7K662K544K516.8K
Other Current Liab12.5M2.5M1.8M1.5M3.0M1.9M
Other Liab4.6M5.9M6.7M6.7M7.7M8.1M
Net Tangible Assets(107.9K)24.8M36.1M26.5M30.5M32.0M
Common Stock Total Equity271.7M285.2M311.1M356.8M410.3M430.9M
Short Term Investments13.1M30.4M1.4M20.5M3.4M3.2M
Short Term Debt339.8K248.9K294K216K133K127.3K
Common Stock311.1M356.8M391.3M404.0M430.9M452.5M
Property Plant Equipment727.5K609.1K976.3K652K749.8K377.8K
Capital Lease Obligations506.3K402.1K654.8K373K423K288.3K
Current Deferred Revenue(3.2K)(1.8K)(594K)(1.1M)(973.8K)(925.1K)
Net Invested Capital(107.9K)24.8M36.1M26.5M27.6M20.3M
Net Working Capital6.1M31.0M42.2M31.7M33.9M26.6M
Capital Stock311.1M356.8M391.3M404.0M430.9M399.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Oncolytics Stock Analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.